Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Pr… (NCT00074191) | Clinical Trial Compass
CompletedPhase 2
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
United States1 participantsStarted 2000-01
Plain-language summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have primary CNS lymphoma.
Who can participate
Age range16 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed intermediate- or high-grade primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis
* Diagnosed within the past 90 days
* No systemic lymphoma NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age
* 16 to 75
Performance status
* ECOG 0-3 OR
* Karnofsky 40-100%
Life expectancy
* Not specified
Hematopoietic
* WBC at least 2,500/mm\^3
* Hematocrit at least 25% (transfusion allowed)
* Absolute granulocyte count at least 1,200/mm\^3
* Platelet count at least 100,000/mm\^3 OR at least lower limit of normal (transfusion independent)
Hepatic
* Bilirubin no greater than 2.0 times upper limit of normal
Renal
* Creatinine clearance at least 30 mL/min
Cardiovascular
* Adequate cardiac function to tolerate general anesthesia
Pulmonary
* Adequate pulmonary function to tolerate general anesthesia
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception for 2 months before and during study participation
* No other uncontrolled, clinically significant confounding medical condition within the past 30 days
* No known allergy to study agents
* HIV negative
PRIO…
What they're measuring
1
Survival as measured by clinical and radiographic response at 5 years following completion of study treatment